Nifty index opened on a negative note and attempted a recovery during the first hour, bouncing up to the 25,330 zone. However, it failed to sustain these gains for the remainder of the day, gradually dipping towards the 25,150 mark. The index’s movement reflects a cautious approach following recent gains, which capped further upside momentum. On the daily chart, Nifty formed a small-bodied candle and closed with a loss of nearly 120 points. It ended the day near its lower band and started to form a pattern of lower highs and lower lows on the daily scale. Despite this, the major trend remains intact on the positive side.

For an upward move, Nifty needs to hold above the 25,200 zone, with potential targets at 25,350 and then 25,500. Conversely, if it fails to sustain above 25,200, further weakness could push it down to 25,100 and then 25,000.

**Option Front**
Maximum Call Open Interest (OI) is concentrated at the 25,300 and 25,500 strikes, while Maximum Put OI is observed at the 25,200 and 25,000 strikes. Call writing is predominantly seen at the 25,300 and 25,250 strikes, with put writing notable at 25,200 and 25,150 strikes. This option data suggests a broader trading range between 24,700 and 25,700 zones, with an immediate trading range expected between 25,000 and 25,400 levels.

—

**S&P BSE Sensex Overview**
The S&P BSE Sensex also opened on a negative note but quickly gained momentum, moving from 82,200 to 82,600 zones. After trading in a tight range of about 200 points, it failed to break above the 82,600 level and slipped back below 82,200 marks towards the session close. The daily chart shows a small-bodied candle with a long upper shadow, indicating selling pressure at higher levels. It closed the day with a loss of around 470 points.

As long as the Sensex holds above the 82,000 zone, strength could re-emerge towards 82,500 and then 82,800. On the downside, supports are placed at 82,000 followed by 81,700 levels.

—

**Bank Nifty Performance**
Bank Nifty opened marginally lower near 55,350 but saw a quick recovery in the early session, extending momentum to 55,650. However, it failed to sustain these higher levels and gradually drifted lower to 55,200 by the end of the day. The index formed a small bearish candle with a long upper shadow on the daily chart, signaling selling pressure at elevated levels. However, it remains above its 10-day exponential moving average (DEMA), which is a positive sign.

To maintain upward momentum, Bank Nifty must hold above 55,250 with targets at 55,750 and 56,000. On the downside, supports are seen at 55,000 and further down at 54,750.

—

**Nifty Futures & Stock Highlights**
Nifty futures closed with a loss of 0.53%, settling at 25,276 levels.

**Stocks Showing Positive Momentum:**
– Adani Green Energy
– Adani Energy Solutions
– HUDCO
– Adani Enterprises
– NBCC
– Muthoot Finance
– Naukri
– Manappuram Finance
– Ambuja Cement
– Polycab

**Stocks Showing Weakness:**
– Coforge
– Mphasis
– KFin Tech
– Cyient
– Tata Technologies
– Voltas
– Titan
– Trent
– TCS
– MGL
– BSE

—

### Technical Call of the Day: Oberoi Realty

Oberoi Realty is currently trading marginally below its key moving averages, but the price structure is showing encouraging signs. The stock is forming higher highs and higher lows, signaling a shift towards positive momentum. Additionally, a positive RSI divergence supports the potential for an upside rally, strengthening the bullish outlook.

**Technical Details:**
– **Recommendation:** Buy
– **Current Market Price (CMP):** Rs. 1,673.90
– **Stop Loss (SL):** Rs. 1,615.00
– **Target (TGT):** Rs. 1,770.00

—

### Top 5 Stocks to Watch on 23rd September 2025

**1. Brigade Enterprises**
Brigade Group has signed a Joint Development Agreement to develop a residential project in Banashankari, 5th Stage, South Bengaluru. Spread over 7.5 acres, the project will deliver thoughtfully designed, high-quality residential spaces. With a gross development value (GDV) of approximately Rs. 1,200 crore, this initiative reinforces Brigade’s commitment to creating premium urban living experiences in Bengaluru’s rapidly growing corridors.

**2. KEC International**
KEC International Ltd. has secured new orders worth Rs. 3,243 crore for Transmission & Distribution projects. Key components include 400 kV transmission lines in the United Arab Emirates (UAE) and the supply of towers, hardware, and poles in the Americas. This order strengthens KEC’s foothold in the Middle East and significantly expands its international T&D order book. The Middle East remains a strategic growth driver for the company. With these orders, the year-to-date order intake stands at approximately Rs. 11,700 crore.

**3. RVNL (Rail Vikas Nigam Limited)**
RVNL emerged as the lowest bidder (L1) from Southern Railway for a contract involving the design, supply, erection, testing, and commissioning of traction substations (Scott-Connected) inclusive of power quality compensating equipment and associated switching posts. This project covers the section from Jolarpettai Junction to Salem Junction in the Southern Railway division and aligns with the Mission 3000MT loading target. The order size is Rs. 145 crore, with an execution timeline of 540 days.

**4. KFin Technologies**
Amid rumors regarding General Atlantic selling 10-15% of its stake in KFin Technologies at a 5-8% discount to the current market price, the company has issued a clarification. KFin Tech categorically denied these reports, calling them inaccurate speculation. The General Atlantic Group, categorized as Promoter and Promoter Group, has not indicated any intention to sell their stake to the management or Board of Directors.

**5. Dr. Reddy’s Laboratories**
Dr. Reddy’s Laboratories and its subsidiaries announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending marketing authorization for AVT03, a biosimilar of Prolia® and Xgeva®. Prolia® is used to treat osteoporosis and bone loss due to menopause, prostate cancer therapy, or long-term glucocorticoid use. Xgeva® is prescribed to prevent bone complications in advanced cancer and to treat giant cell tumors of bone in adults and adolescents. This approval paves the way for AVT03’s launch in European markets.

—

*Stay tuned for further updates and market insights.*
https://www.freepressjournal.in/business/market-outlook-technical-call-of-the-day-top-5-stocks-in-focus-for-23rd-sept-2025